Prothena Swings to Profit in Q1 with $51M Revenue, Driven by Novo Nordisk Milestone
PRTA has more than doubled off its 52-week low of $4.32.
Summary
Prothena reported a strong first quarter 2026, achieving $51.08 million in revenue and $0.6 diluted EPS, marking a significant swing to a net income of $32.72 million from a loss in the prior-year quarter. This impressive performance was primarily driven by a $50 million milestone payment from Novo Nordisk. The results represent a substantial turnaround from the $244.1 million net loss reported for the full year 2025 and exceed prior projections of merely reducing cash burn. Furthermore, the company advanced two key programs, prasinezumab and coramitug, into Phase 3 trials, supported by positive Phase 2 data. This financial strength and pipeline progress significantly de-risk the company and provide strong positive momentum for investors.
At the time of this announcement, PRTA was trading at $10.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $566.3M. The 52-week trading range was $4.32 to $11.69. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.